Paydas, S. 2016. Pulmonary sarcoidosis induced by the anti-PD-1 monoclonal antibody pembrolizumab or post-immunotherapy granulomatous reaction: which is more appropriate terminology?. ANNALS OF ONCOLOGY , vol.27, no.8 , 1650-1651.

Paydas, S., (2016). Pulmonary sarcoidosis induced by the anti-PD-1 monoclonal antibody pembrolizumab or post-immunotherapy granulomatous reaction: which is more appropriate terminology?. ANNALS OF ONCOLOGY , vol.27, no.8, 1650-1651.

Paydas, SEMRA. "Pulmonary sarcoidosis induced by the anti-PD-1 monoclonal antibody pembrolizumab or post-immunotherapy granulomatous reaction: which is more appropriate terminology?," ANNALS OF ONCOLOGY , vol.27, no.8, 1650-1651, 2016

Paydas, SEMRA. "Pulmonary sarcoidosis induced by the anti-PD-1 monoclonal antibody pembrolizumab or post-immunotherapy granulomatous reaction: which is more appropriate terminology?." ANNALS OF ONCOLOGY , vol.27, no.8, pp.1650-1651, 2016

Paydas, S. (2016) . "Pulmonary sarcoidosis induced by the anti-PD-1 monoclonal antibody pembrolizumab or post-immunotherapy granulomatous reaction: which is more appropriate terminology?." ANNALS OF ONCOLOGY , vol.27, no.8, pp.1650-1651.

@article{article, author={SEMRA PAYDAŞ}, title={Pulmonary sarcoidosis induced by the anti-PD-1 monoclonal antibody pembrolizumab or post-immunotherapy granulomatous reaction: which is more appropriate terminology?}, journal={ANNALS OF ONCOLOGY}, year=2016, pages={1650-1651} }